MedTrace Logo

The Use of Low Molecular Weight Heparin in Hemodiafiltration

NCT00756145 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-05-14

No results posted yet for this study

Summary

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Conditions

Interventions

PROCEDURE

At start of the session, at the inlet line

Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

PROCEDURE

5 minutes after the start of the session, at the inlet line

Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

PROCEDURE

At the start of the session, at the outlet line

Injection of LMWH at the outlet line, at the start of the hemodiafiltration session

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Annemieke Dhondt, MD, PhD · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00756145 on ClinicalTrials.gov